Oboravo 25mg Tablet contains Empagliflozin, a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated for the management of type 2 diabetes mellitus. By inhibiting SGLT2 in the proximal renal tubules, Empagliflozin reduces glucose reabsorption, promoting urinary glucose excretion and thereby lowering plasma glucose levels. This mechanism contributes to improved glycemic control, which is essential in reducing the risk of diabetes-related complications. Oboravo 25mg is typically prescribed as an adjunct to diet and exercise, either as monotherapy or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. Clinical studies have demonstrated its efficacy in lowering HbA1c, fasting plasma glucose, and body weight, with additional cardiovascular and renal benefits observed in patients with established cardiovascular disease or chronic kidney disease. Common adverse effects include genital mycotic infections, urinary tract infections, and increased urination. Caution is advised in patients with renal impairment, hypotension, or a history of ketoacidosis. Regular monitoring of renal function and glycemic parameters is recommended during therapy. Oboravo 25mg should be used under medical supervision, with dosage adjustments based on individual patient response and tolerability.